Bone Metastases From Solid Tumors

2

Review clinical trials related to Bone Metastases From Solid Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.

Participants needed: 125
Trial details
Age: Up to 85Biological sex: AllType: ObservationalSponsor: Istituto Ortopedico RizzoliUpdated: Aug 8, 2025Locations: 1
Eligibility criteria

Patients (male or female) diagnosed with sarcoma or with bone or lung metastases... [+4]

Diagnosis other than sarcoma or metastases from solid tumors [+1]

Status: Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kiromic BioPharma Inc.Updated: Mar 5, 2025Locations: 5
Eligibility criteria

Signed and dated informed consent form. [+13]

Chemotherapy, investigational, and/or check-point inhibitor therapy within the 3... [+14]